Medical Marijuana, Inc. owns approximately 16.7% of Kannalife Sciences™
Kannalife™ Sciences, Inc. is a biomedical company involved in the research and development of novel treatments designed to capitalize on the antioxidant and neuroprotective properties of cannabinoids. Kannalife™ Sciences currently holds exclusive licenses from the National Institutes of Health for the commercialization of U.S. Patent #6,630,507, “Cannabinoids as Antioxidants and Neuroprotectants.”
The scientific team at Kannalife™ is comprised of dedicated professionals, clinicians, and biochemists, all of whom have a strong background in phyto-pharmaceutical and biological sciences. They have a well established track record of successfully developing drugs from plant sources that are complex in nature and structure.
Their researchers are currently conducting research and development utilizing this patent for a target drug candidate to treat the oxidative brain diseases hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE) at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA.
Kannalife™ intends to move forward with its plan to design a novel new drug compound for the treatment of hepatic encephalopathy (HE). HE is a neurodegenerative disease caused by cirrhosis of the liver, or similar liver conditions. Kannalife™ believes its target drug candidate will be comprised of one or more cannabinoid(s) for use and delivery in humans as FDA approved drugs. There is a large market for an effective HE treatment in the U.S.; there are currently over 1.5 million sufferers of hepatic encephalopathy in the United States.
Kannalife™ also plans to develop cannabinoid-based treatments for chronic traumatic encephalopathy (CTE). CTE is a neurodegenerative disease of the brain and is associated with repeated head traumas like concussions. CTE has been most commonly found in professional athletes participating in contact sports who have experienced repetitive brain trauma. It has also been found in soldiers exposed to a blast or a concussive injury.
Neurodegenerative diseases have historically been difficult to treat, and there are no universally accepted treatments for the range of conditions associated with these diseases. There is an imperative need for both preventative measures and prescription treatments that are able to address the core causes of neurodegenerative diseases, creating an urgency for Kannalife™ Sciences to develop unique and innovative new cannabinoid-based drugs.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.
* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.